anti-CD3/anti-CD19 bispecific T-cell engager TYC-201 nanorings (Tychon Bioscience)

N/A

Report date: 2026/03/19 16:58:31

Base Information

Drug Nameanti-CD3/anti-CD19 bispecific T-cell engager TYC-201 nanorings (Tychon Bioscience)
Drug Alias Nameanti-CD3/anti-CD19 bispecific prosthetic antigen receptor T-cell therapy chemically self-assembled nanorings (Tychon Bioscience)anti-CD3/anti-CD19 bispecific PAR T-cell therapy TYC-201 nanorings (Tychon Bioscience)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Recombinant protein > Fusion protein +[4] 
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT cell surface glycoprotein CD3 modulators
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTychon Bioscience Inc
China Registration ClassN/A

Develop Information

Active CompaniesTychon Bioscience Inc
Inactive CompaniesN/A
Active IndicationsLymphomaLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A